A Cambridge biotechnology company is eliminating nearly its entire workforce after federal regulators determined its only drug posed an unacceptable cancer risk. The move eliminates 48 positions and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Cambridge biotech notified ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...

Fulcrum Therapeutics will lay off the majority of its workforce after it said it would terminate the development of a sickle-cell-disease treatment. The company on Thursday said it expects to reduce ...

With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fulcrum Therapeutics (FULC) lost nearly 50% of its value in extended trading after the company disclosed plans to discontinue the development of its lead asset, pociredir, for sickle cell disease in ...

The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and organ damage and reduce life expectancy. Sign up here. Pociredir ...

Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. Ipsen ...

June 1 (Reuters) - Fulcrum Therapeutics (FULC.O), opens new tab said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised ...

Fives ProSim, a subsidiary of the Fives Group and an expert in industrial process simulation and optimization, announces the release of ProSimPlus Python API. This new solution enables users to run ...